ReviewEuropean archives of psychiatry and clinical neuroscience2005
Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?
Review in European archives of psychiatry and clinical neuroscience, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 82 citations in OpenAlex.
- Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.BMC psychiatry · 2011Trial
- Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro).Journal of clinical psychopharmacologyTrial
- Effects of Psychotropic Drugs on Seizure Threshold during Electroconvulsive Therapy.Psychiatry investigation · 2017Article
- ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety.Naunyn-Schmiedeberg's archives of pharmacology · 2016Article
- Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders.Frontiers in psychiatry · 2013Review
- Can we really prevent suicide?Current psychiatry reports · 2012Review
- Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers.British journal of clinical pharmacology · 2012Article
- Forms of antipsychotic therapy: improved individual outcomes under personalised treatment of schizophrenia focused on depression.The EPMA journal · 2011Article
- Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.Psychopharmacology · 2011Review
- Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia.Schizophrenia research and treatment · 2011Article
- [Genetics of weight gain associated with antipsychotic medications].Der Nervenarzt · 2009Review
- Evidence for separate diseases?: Stages of one disease or different combinations of symptom dimensions?European archives of psychiatry and clinical neuroscience · 2008Article
- A dynamical systems hypothesis of schizophrenia.PLoS computational biology · 2007Article
- Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder.CNS drugs · 2007Review
- [Antipsychotic drug-induced changes in metabolism].Wiener klinische Wochenschrift · 2006Review
- Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review.European archives of psychiatry and clinical neuroscience · 2006Review
- Adverse effects of atypical antipsychotics in the elderly: a review.Drugs & aging · 2006Review
- Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data.European archives of psychiatry and clinical neuroscience · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Second generation antipsychotics display antidepressive effects in schizophrenic patients that are more pronounced than those of traditional neuroleptics and that go beyond antidepressive effects secondary to the reduction of positive symptoms. The antidepressive potential of second generation antipsychotics is presumably related to their pharmacological mechanisms, which differ from those of traditional neuroleptics. Among others, 5-HT(2A) antagonism is of special relevance for most of the new antipsychotics in this respect. But also special interactions with the dopaminergic system, as is the case with amisulpride and aripiprazole, or noradrenalin- and/or serotonin-reuptake-inhibition, as with ziprasidone and zotepine, should be considered. It can be summarised that the antipsychotic and antidepressive effects of second generation antipsychotics are mostly based on different pharmacological mechanisms. This might be especially true for direct antidepressive effects, i. e. antidepressive effects that are not mediated by the reduction of positive symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.